Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Shares of drugmaker Bristol Myers Squibb rose 7% in premarket trading Monday after it said the Food and Drug Administration approved a key medication.

Bristol Myers Stock Jumps as U.S. Approves Psoriasis Drug

Bristol Myers Squibb BMY, +1.12% shares rose 7% in premarket trade after the company said the U.S. Food and Drug Administration approved Sotyktu, which the drugmaker said was the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years. Bristol Myers Squibb said the approval came after Phase 3 trials found it was more effective compared to placebo and twice-daily Otezla, made by Amgen AMGN, +0.91%.

Bristol Myers Squibb rallies after FDA approves Sotyktu for psoriasis

Archer-Daniels-Midland Company

Cigna

SPDR Dow Jones Industrial Average ETF

Ford Motor Company

First Trust NASDAQ Technology Dividend Index Fund

Figuring out which blue-chip stocks to buy before the bull market returns can be a challenge. So far, declines on Wall Street have pushed the major averages into bear market territory.

7 Blue-Chip Stocks to Buy Before the Bull Market Returns

Bristol Myers Squibb showed substantial strength in the last months compared to the market. In the last weeks, momentum began to weaken due to some mixed pipeline updates and upcoming concerns about the long-term strategy.

Bristol Myers Squibb: Still A Buy Despite Some Concerns

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #doctor--FDA approves SOTYKTU for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

BMY is down 12% from the 12-month high in late June, but has returned 13.9% for the YTD. The company maintained solid earnings growth through COVID and beyond.

Stronger Outlook For Bristol-Myers Squibb

Do not be intimidated by market turbulence.

2 Top Stocks to Buy In September and Hold Forever

Bristol-Myers Squibb Co. ( BMY , Financial) should stand up and take a bow. Its acquisition of Medarex in 2009 has proved to be one of the most successful buyouts in recent memory, given the cancer drug Opvido that was procured in the deal has returned nearly 35 times the original investment.

Bristol-Myers Tops List of Most Successful Company Buyouts

Bristol-Myers Squibb Company (NYSE:BMY ) Citi's 17th Annual BioPharma Conference September 8, 2022 8:50 AM ET Company Participants Adam Lenkowsky - Head of U.S. Commercialization Roland Chen - Head of Cardiovascular Development Tim Powers - Head of Investor Relations Conference Call Participants Andrew Baum - Citi Andrew Baum Start the Bristol-Myers Squibb session. So delighted to introduce our guests from Bristol-Myers Squibb today.

Bristol-Myers Squibb Company (BMY) Presents at Citi's 17th Annual BioPharma Conference (Transcript)

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022

Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

A promising cancer drug combo from Bristol Myers Squibb is months away from being approved in the European Union to treat patients with a form of skin cancer.

Is This Monster Stock On Its Way to Another Multibillion-Dollar Drug?

Booking Hlds

Ovintiv

Alphabet

Michael Burry made a name for himself during the Great Recession. His bearish bet against the housing market made the contrarian investor a fortune.

5 Stocks That Michael Burry Just Dumped From His Portfolio

Bristol Myers Squibb stock (NYSE: BMY) was down 6% in yesterday's trade, while it's down around 10% in a month.

Down 6% In A Day, Will Bristol Myers Squibb Stock Rebound?

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference

Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference

AbbVie

Amgen

CVS Health

Gilead Sciences

Eli Lilly

Merck

Pfizer

The stock market rally ran into the harsh reality last Friday that any interest rate pivot by the Federal Reserve may not come until 2024.

8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends

APA Corporation

Cardinal Health

CF Industries Holdings

Catalent

Diamondback Energy

Johnson & Johnson

Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.

S&P 500 Stock Market Winners Today

The drugmaker's next-generation blood thinner fails to impress in a mid-stage trial.

Why Bristol Myers Squibb Stock Is Slumping Today

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.

Bristol Myers (BMY) Announces Milvexian Phase II Study Results

While the therapy, milvexian, showed a 30% risk reduction in recurrent ischemic strokes among people who showed symptoms, it didn't have an effect on covert infarcts, eroding investor confidence.

Bristol Myers Stock Falls After Stroke Medicine Misses the Mark

Bayer AG

Bristol Myers and Johnson & Johnson's blood thinner fell short of expectations in stroke patients, leading BMY stock to crumble on Monday. The post Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops appeared first on Investor's Business Daily.

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops

Investors should keep an eye on developments at the European Society of Cardiology meeting, which is underway in Barcelona. News about a new type of heart drug being tested by Bristol-Myers Squibb Co. ( BMY , Financial), Johnson & Johnson ( JNJ , Financial) and Bayer AG ( XTER:BAYN , Financial) could potentially move the shares of the three pharmaceutical giants.

Bristol-Myers, J&J and Bayer Presenting Key Study Results at Heart Meeting

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AXIOMATIC--Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian

Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy

News for Bristol-Myers Stock (BMY)